Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 1.00 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14489499 | 0.86 | IDO1 (0.75) | IDO1NOTUMCYP3A4CYP2A6CYP11B1 | |
| SCHEMBL5546083 | 0.81 | IDO1 (0.69) | IDO1NOTUMCYP3A4CYP2A6CYP11B1 | |
| SCHEMBL8333337 | 0.80 | IDO1 (0.67) | IDO1NOTUMCYP3A4CYP2A6CYP11B1 | |
| SCHEMBL14062190 | 0.79 | IDO1 (0.65) | IDO1NOTUMCYP3A4CYP11B1CYP11B2 | |
| SCHEMBL16716592 | 0.79 | IDO1 (0.65) | IDO1NOTUMCYP3A4CYP2A6CYP11B1 | |
| SCHEMBL25138280 | 0.78 | IDO1 (0.64) | IDO1NOTUMCYP3A4CYP2A6CYP11B1 | |
| SCHEMBL10346856 | 0.78 | IDO1 (0.64) | IDO1NOTUMCYP3A4CYP2A6CYP11B1 | |
| SCHEMBL3152446 | 0.78 | IDO1 (0.64) | IDO1NOTUMCYP3A4CYP2A6CYP11B1 | |
| SCHEMBL22114976 | 0.78 | IDO1 (0.64) | IDO1NOTUMCYP3A4CYP2A6CYP11B1 | |
| SCHEMBL21020697 | 0.78 | IDO1 (0.64) | IDO1NOTUMCYP3A4CYP2A6CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-01-14 | — | — | US | claimed |
| CN-117894971-B | Glassy metal organic framework material modified ternary positive electrode material, and preparation method and application thereof | 中南大学 | 2024-06-04 | — | — | CN | claimed |
| US-20200171474-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY | 2020-06-04 | — | — | US | claimed |
| WO-2018213821-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY (US) | 2018-11-22 | — | — | WO | claimed |
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| CN-117894971-B | Glassy metal organic framework material modified ternary positive electrode material, and preparation method and application thereof | 中南大学 | 2024-06-04 | — | — | CN | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-4222151-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE | Shanghai Yao Yuan Biotechnology Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-20200171474-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY | 2020-06-04 | — | — | US | disclosed |
| EP-3032625-B1 | FUEL CELL SEPARATOR | NISSHINBO CHEMICAL INC (JP) | 2020-01-08 | — | — | EP | disclosed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| CN-101027075-A | Combination therapy for the treatment of obesity | MERCK & CO INC (US) | 2007-08-29 | — | — | CN | disclosed |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. | 2006-10-12 | — | — | US | disclosed |
| EP-1694410-A2 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005058884-A2 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
| EP-0281121-A1 | 1-(1-Aryl-2-hydroxy-ethyl)-imidazoles and their salts, processes for their preparation, drugs containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | IDO1 4007/4885NOTUM 2266/4885CYP3A4 2309/4885 |
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | MLX, LDHA, CA2 | IDO1 2134/4885NOTUM 3924/4885CYP3A4 3701/4885 |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | SLC1A2, SLC1A1, GLRA1 | IDO1 1192/4885NOTUM 2463/4885CYP3A4 1013/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | IDO1 2411/4885NOTUM 4529/4885CYP3A4 4562/4885 |
| US-20200171474-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | MLX, LDHA, CA2 | IDO1 2134/4885NOTUM 3924/4885CYP3A4 3701/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | IDO1 2411/4885NOTUM 4529/4885CYP3A4 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.